News

#myEUspace competition by EUSPA

Published on | 4 years ago

Programmes
Digital, Industry & Space

The European Union Agency for the Space Programme (EUSPA) announced a new competition that targets innovators and entrepreneurs ready to develop and commercialise innovative solutions that leverage EU space data and services.

The objective of the competition is to support the development of innovative commercial solutions - such as mobile apps or hardware-based solutions, for example wearables, asset management and tracking solutions, robotics etc. - that are leveraging EU Space data from Galileo and/or Copernicus.

#myEUspace competition is part of the European Commission Casssini initiative and consists of 2 independent and parallel tracks:

  • Track 1 – From Idea to Prototype/customer validation.
  • Track 2 – From Prototype to Product /Market entry.

Application deadline: 15th November 2021 (23:59 CET).

More information can be found on the EUSPA website

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1899 articles available search in articles 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.